Novartis Inks $670M Deal For Kidney Treatment Drug
Novartis AG has entered into a $670 million licensing deal with privately held Quark Pharmaceuticals Inc. for an experimental drug that helps prevent kidney injury, Quark said Wednesday....To view the full article, register now.
Already a subscriber? Click here to view full article